DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) – Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
There are mainly two types of lung cancer Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers (IASLC, n.d.). However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC.
NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid carcinomas.
In the United States, according to the data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH) out of the total lung cancer cases approximately 85% of lung cancers are NSCLC. Among those cases, squamous cell carcinoma comprised 30% cases, adenocarcinoma comprised of 40% cases, and large-cell carcinoma comprised 15% cases. Also, all other country based registries have mentioned almost same percentage for NSCLC and its major subtypes.
- As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
- As per the DelveInsight estimates, the total incident cases of NSCLC patients by histology in the 7MM were observed to be 142,566, 228,106, 57,027, and 57,027 cases of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
According to the current scenario of NSCLC and our analysis majority of patients fall into two mutations i.e. PD-L1 and EGFR with major percentage share in the market.
Request for a free sample copy of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market
Table of contents:
1 Key Insight
2 Executive Summary of Non-small cell lung cancer (NSCLC)
3 Non-small cell lung cancer (NSCLC) Market Overview at a Glance
4 Disease Background and Overview: Non-small cell lung cancer (NSCLC)
5 Case Reports
6 Non-small cell lung cancer (NSCLC) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Non-small cell lung cancer (NSCLC) Treatment and Medical Practices
11 Unmet needs
12 Non-small cell lung cancer (NSCLC) Marketed Drugs
13 Non-small cell lung cancer (NSCLC) Emerging Drugs
14 Non-small cell lung cancer (NSCLC) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Non-small cell lung cancer (NSCLC) Market Drivers
19 Non-small cell lung cancer (NSCLC) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States